These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 17111204

  • 21. Tissue-type plasminogen activator transgenic rats for evaluating inhibitors of the activated form of thrombin-activatable fibrinolysis inhibitor.
    Ito Y, Noguchi K, Morishima Y, Yamaguchi K.
    Blood Coagul Fibrinolysis; 2018 Apr; 29(3):314-321. PubMed ID: 29538006
    [Abstract] [Full Text] [Related]

  • 22. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis.
    Foley JH, Kim P, Nesheim ME.
    J Biol Chem; 2008 Apr 04; 283(14):8863-7. PubMed ID: 18252711
    [Abstract] [Full Text] [Related]

  • 23. Insights into thrombin activatable fibrinolysis inhibitor function and regulation.
    Foley JH, Kim PY, Mutch NJ, Gils A.
    J Thromb Haemost; 2013 Jun 04; 11 Suppl 1():306-15. PubMed ID: 23809134
    [Abstract] [Full Text] [Related]

  • 24. A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor.
    Morishima Y, Honda Y.
    J Thromb Thrombolysis; 2019 Jul 04; 48(1):103-110. PubMed ID: 30972711
    [Abstract] [Full Text] [Related]

  • 25. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor.
    Ammollo CT, Semeraro F, Incampo F, Semeraro N, Colucci M.
    J Thromb Haemost; 2010 Apr 04; 8(4):790-8. PubMed ID: 20088944
    [Abstract] [Full Text] [Related]

  • 26. New insights into factors affecting clot stability: A role for thrombin activatable fibrinolysis inhibitor (TAFI; plasma procarboxypeptidase B, plasma procarboxypeptidase U, procarboxypeptidase R).
    Bouma BN, Meijers JC.
    Semin Hematol; 2004 Jan 04; 41(1 Suppl 1):13-9. PubMed ID: 14872415
    [Abstract] [Full Text] [Related]

  • 27. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke.
    Kraft P, Schwarz T, Meijers JC, Stoll G, Kleinschnitz C.
    PLoS One; 2010 Jul 19; 5(7):e11658. PubMed ID: 20657835
    [Abstract] [Full Text] [Related]

  • 28. The hyperfibrinolytic state of mice with combined thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 gene deficiency is critically dependent on TAFI deficiency.
    Vercauteren E, Peeters M, Hoylaerts MF, Lijnen HR, Meijers JC, Declerck PJ, Gils A.
    J Thromb Haemost; 2012 Dec 19; 10(12):2555-62. PubMed ID: 23083123
    [Abstract] [Full Text] [Related]

  • 29. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
    Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, Gresele P.
    Hepatology; 2003 Jul 19; 38(1):230-7. PubMed ID: 12830006
    [Abstract] [Full Text] [Related]

  • 30. Argatroban enhances fibrinolysis by differential inhibition of thrombin-mediated activation of thrombin activatable fibrinolysis inhibitor and factor XIII.
    Nielsen VG, Kirklin JK.
    Blood Coagul Fibrinolysis; 2008 Dec 19; 19(8):793-800. PubMed ID: 19002046
    [Abstract] [Full Text] [Related]

  • 31. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent.
    Bajzar L, Nesheim ME, Tracy PB.
    Blood; 1996 Sep 15; 88(6):2093-100. PubMed ID: 8822928
    [Abstract] [Full Text] [Related]

  • 32. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
    Colucci M, D'Aprile AM, Italia A, Gresele P, Morser J, Semeraro N.
    Thromb Haemost; 2001 Apr 15; 85(4):661-6. PubMed ID: 11341502
    [Abstract] [Full Text] [Related]

  • 33. Activated thrombin-activatable fibrinolysis inhibitor attenuates spontaneous fibrinolysis of batroxobin-induced fibrin deposition in rat lungs.
    Wu C, Dong N, da Cunha V, Martin-McNulty B, Tran K, Nagashima M, Wu Q, Morser J, Wang YX.
    Thromb Haemost; 2003 Sep 15; 90(3):414-21. PubMed ID: 12958609
    [Abstract] [Full Text] [Related]

  • 34. Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice.
    Renckens R, Roelofs JJ, ter Horst SA, van 't Veer C, Havik SR, Florquin S, Wagenaar GT, Meijers JC, van der Poll T.
    J Immunol; 2005 Nov 15; 175(10):6764-71. PubMed ID: 16272333
    [Abstract] [Full Text] [Related]

  • 35. Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis.
    Miljić P, Heylen E, Willemse J, Djordjević V, Radojković D, Colović M, Elezović I, Hendriks D.
    Srp Arh Celok Lek; 2010 Jan 15; 138 Suppl 1():74-8. PubMed ID: 20229688
    [Abstract] [Full Text] [Related]

  • 36. Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism.
    Colucci M, Binetti BM, Tripodi A, Chantarangkul V, Semeraro N.
    Blood; 2004 Mar 15; 103(6):2157-61. PubMed ID: 14630828
    [Abstract] [Full Text] [Related]

  • 37. Thrombin activatable fibrinolysis inhibitor: at the nexus of fibrinolysis and inflammation.
    Colucci M, Semeraro N.
    Thromb Res; 2012 Mar 15; 129(3):314-9. PubMed ID: 22113149
    [Abstract] [Full Text] [Related]

  • 38. Thrombin activatable fibrinolysis inhibitor: not just an inhibitor of fibrinolysis.
    Bajzar L, Jain N, Wang P, Walker JB.
    Crit Care Med; 2004 May 15; 32(5 Suppl):S320-4. PubMed ID: 15118538
    [Abstract] [Full Text] [Related]

  • 39. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation.
    Myles T, Nishimura T, Yun TH, Nagashima M, Morser J, Patterson AJ, Pearl RG, Leung LL.
    J Biol Chem; 2003 Dec 19; 278(51):51059-67. PubMed ID: 14525995
    [Abstract] [Full Text] [Related]

  • 40. Thrombin-activatable fibrinolysis inhibitor in hypothyroidism and hyperthyroxinaemia.
    Verkleij CJ, Stuijver DJ, van Zaane B, Squizzato A, Brandjes DP, Büller HR, Meijers JC, Gerdes VE.
    Thromb Haemost; 2013 Feb 19; 109(2):214-20. PubMed ID: 23197299
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.